Status:
COMPLETED
Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Granulomatous Disease
Chronic
Eligibility:
All Genders
Phase:
PHASE1
Brief Summary
This protocol is designed for a single specific patient. It uses busulfan as a conditioning agent in a second stem cell transplant procedure for a patient with chronic granulomatous disease (CGD), a d...
Detailed Description
This is a single patient study using intravenous busulfan as a conditioning agent for a second allogeneic stem cell transplant in order to increase myeloid engraftment in a previously transplanted rec...
Eligibility Criteria
Inclusion
- RECIPIENT INCLUSION/EXCLUSION CRITERIA:
- The recipient fulfills by study design the inclusion criteria
- The patient however, would be considered ineligible for the study only If his donor is unable to participate.
- DONOR EXCLUSION CRITERIA:
- Pregnant or lactating.
- Donor unfit to receive G-CSF and undergo apheresis. (Uncontrolled hypertension, history of congestive heart failure or unstable angina, thrombocytopenia).
- HIV positive.
Exclusion
Key Trial Info
Start Date :
September 23 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 6 2010
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00092937
Start Date
September 23 2004
End Date
April 6 2010
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892